Tabernanthalog

Tabernanthalog (TBG) is a novel water-soluble, non-toxic azepinoindole analog of the psychoactive drug ibogaine first synthesized by Professor David E. Olson at UC Davis.

In rodents, it was found to promote structural neural plasticity, reduce drug seeking behavior, and produce antidepressant like effects. It has also been shown that it effectively reduces motivation for heroin and alcohol in rats. This indicates its efficacy in animals with a history of heroin and alcohol polydrug use.

Due to the rapidly-induced and enduring neuroplasticity, tabernanthalog is a member of the class of compounds known as non-hallucinogenic psychoplastogens. This compound, as well as related compounds, are licensed by Delix Therapeutics and are being developed as potential medicines for neuropsychiatric disorders.